Skip to main content
ResearchTreatments

Synopsis Clinical Trial: Open for Enrollment

*March 2022*

This is a Phase II randomized trial of carboplatin + pemetrexed + bevacizumab with or without atezolizumab in stage 4 non-squamous NSCLC patients who harbor a sensitizing EGFR mutation or have never smoked. Learn more here.